Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction

M

Ministry of Health, Israel

Status and phase

Unknown
Early Phase 1

Conditions

Drug Abuse

Treatments

Drug: Opipramol
Drug: Baclofen

Study type

Interventional

Funder types

Other

Identifiers

NCT03065998
066-2017 MOH

Details and patient eligibility

About

The aim of this study is examining the combination of two FDA approved drugs, Opipramol and baclofen, which may increase rehabilitation from psychoactive substances. Previous studies have indicated a connection of sigma-1 receptor to cocaine abuse and raised the possibility that these receptors as mediators of drug craving . However previous studies showed partial efficacy with no significant relapse in relapse rates. The same is true for the use of GABAb-1 receptor antagonist. Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent. Moreover, previous open and controlled trials indicated that the GABAb-1 antagonist baclofen partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine. Our studies in an animal model for addiction have shown a significant effect of the combine treatment of the indicated medications both in decreasing relapse and increase of -number of respondents.

Enrollment

140 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age will be 60-18, both sexes, seeking treatment in order to stop the consumption of materials

Exclusion criteria

Did not include trial addicts with co-morbidity, kidney, heart, metabolic, neurological and psychiatric disorders (psychosis, chronic depression).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

140 participants in 2 patient groups

Drug-A
Active Comparator group
Description:
opripramol 150 mg per day (3*50) Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent.
Treatment:
Drug: Baclofen
Drug: Opipramol
Drug-B
Active Comparator group
Description:
baclofen 90 mg per day (3*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine.
Treatment:
Drug: Baclofen
Drug: Opipramol

Trial contacts and locations

0

Loading...

Central trial contact

Paola Roska, MD; Keren Goldman, MsC

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems